Opportunities
Search

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Patient-Centered Outcomes and Survivorship Award (PCOSA) promotes evidence-based and patient-centered approaches to improve health and lung cancer related outcomes and enhance the patient experience in defined populations. Research must address at least one of the FY26 LCRP areas of emphasis in the Health Outcomes and Survivorship category.Distinctive Features:• This funding mechanism requires the research team to include an advocate who is a lung cancer patient/survivor or caregiver.• This funding mechanism allows proposed projects to include translational or clinical research, including pilot clinical trials.

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. This mechanism promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation. Research must address at least one of the FY26 LCRP areas of emphasis.Distinctive Features: This FY26 LCRP IDA mechanism has a New Investigator category that is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.Distinctive Features: This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1 – Advanced/late-stage preclinical work or correlative studies; or Funding Level 2 – Pilot clinical trials of novel interventions.

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Data Science Award (DSA) supports research that develops or uses quantitative and analytical approaches, processes and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data in one or more of the following research areas: Analysis of clinically annotated datasets; analysis of -omics data; artificial intelligence and machine learning; bioinformatics; computational biology; digital pathology; epidemiology; and medical imaging. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (EIRA) supports prostate cancer research conducted by investigators in the early stages of their careers with guidance from an experienced mentor. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        Early-Career Investigator: Serves as the principal investigator. Includes investigators possessing a doctoral degree or equivalent with fewer than three years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training. ·        Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship. ·        Researcher Development Plan: Applications must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the Principal Investigator’s (PI’s) career development

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Physician Research Award (PRA) Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        Early-Career Clinician Investigator: Serves as the Principal Investigator (PI). Includes investigators with clinical duties in the last year of an accredited medical residency or medical fellowship program, or within five years of initiating a faculty appointment. ·        Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship. ·        Researcher Development Plan: Applications must include a research development plan articulating an individualized strategy for acquiring necessary skills, competence and expertise to complete the projects and foster the PI’s career development. https://cdmrp.health.mil/pubs/press/2026/pcrppreann

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. All applications must address one of the FY26 PCRP Overarching Challenges. Distinctive Features: ·        New Investigator Category: In addition to established investigators, the FY26 PCRP Idea Development Award encourages research ideas from investigators in the early stages of their careers (i.e., within 10 years after completion of their terminal degree). Qualified new investigators must identify a collaborator(s) experienced in prostate cancer research.   https://cdmrp.health.mil/pubs/press/2026/pcrppreann

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 Enhancing Security Measures for Houses of Worship Program. This opportunity provides grants to enhance security and law enforcement capabilities at faith-based institutions and houses of worship to prevent and respond to bias-motivated crimes. Projects will strengthen partnerships between religious communities and local law enforcement, implement evidence-based security measures, and build institutional capacity to report incidents and assist in criminal investigations.

Expected Outcome:Actions funded under this Call are expected to contribute to: Increased participation of under-represented groups in entrepreneurial activities; Improved access to tailored incubation services and financing opportunities for aspiring entrepreneurs facing structural barriers; Enhanced entrepreneurial skills, business readiness and sustainability of supported enterprises; Strengthened cooperation between incubation providers, financial actors and employment or social inclusion stakeholders; Development of innovative, evidence-based approaches, as a possible source of inspiration for other initiatives; Improved knowledge and policy learning regarding effective inclusive entrepreneurship support mechanisms. In the longer term, the Call is expected to contribute to more inclusive labour markets, job creation, strengthened social economy ecosystems and reduced inequalities in...

Expected Outcome:Objectives and profile of the ERC Plus Grant Principal InvestigatorThe ERC Plus Grant supports outstanding Principal Investigators who address a major scientific challenge. Applications for ERC Plus Grants should be for projects that could not be carried out with a regular ERC grant. Applicants should explain how the proposed project aims go beyond those of a regular ERC project, for example, because they have a vision to transform their field or open a new field of research. Scholars at all career stages can apply for an ERC Plus Grant if they have an outstanding record of scientific achievement at the forefront of their field. Their intellectual leadership will be evaluated in comparison to peers at their own career stage.It is expected that a researcher may be the Principal Investigator of only one ERC Plus Grant in their lifetime. Applicants should be aware that ever...

The NIH Director"s Transformative Research Award supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications in any area within the biomedical sciences are welcome; topics may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Director"s Transformative Research Award is a component of the High-Risk, High-Reward Research (HRHR) program of the NIH Common Fund.

This is a notice of funding opportunity (NOFO) for the BJA FY 2026 Daniel Anderl Judicial Security and Privacy Program. This opportunity supports states and units of local government, including tribal governments that perform law enforcement functions, in creating and expanding efforts to protect the safety and security of federal judges by preventing the release of covered information about at-risk individuals and their immediate family members to ensure federal judges are able to administer justice fairly without fear of personal reprisal from individuals affected by the decisions they make in the course of carrying out their public duties. Many federal judges' personal information resides in state and local government records, databases, and registries that are publicly accessible and searchable and outside federal control. Grants to state and local entities support federal-state-local partnerships to protect federal judicial officers and their families. Funds awarded under this grant program must be used exclusively for protecting federal judges and their immediate family members as defined in statute. Applicants that have existing judicial protection programs should clearly delineate how grant funds will be used solely for federal judges and describe cost allocation methodologies to ensure appropriate separation of expenses. Expenses that also benefit other judges are acceptable, provided that any costs specific to state, local, or tribal judges are separately tracked and are not charged to this grant.

Expected Impact:In the long-term, the funding is expected to:have increased operational capacity of law enforcement authorities to fight organised crime, including an improved capability to trace and untangle complex money laundering schemes.have improved cross-border cooperation and sharing of challenges and best practices in fighting against organised crime.have improved detection, identification and referral of victims of crime in the context of cross-border operational actions, as well as improved protection of victims in criminal proceedings, in cooperation with civil society organisations. Expected Outcome:Projects should aim to achieve one or more of the following outcomes:increase understanding of the nature and modus operandi of criminal networks and key actors and enablers.enhance coordination of law enforcement authorities in cross-border operations and support multi-stakehold...

Expected Impact:In the long-term, the funding is expected to:have increased operational capacity of law enforcement and other security-oriented authorities to fight organised crime and drug production and trafficking, including an improved capability to trace and untangle complex money laundering schemes as well as illicit flows of goods.enhance risk assessments and risk awareness and resilience measures in view of anticipating, preventing and tackling organised crime and drug related crimes.have improved cross-border cooperation including with key third countries and information exchange (including where possible and applicable with the private sector) and sharing of challenges and good practices in fighting against organised crime.have improved detection, identification and referral of victims of crime in the context of cross-border operational actions, as well as improved protection o...

Scope:CENTRES OF VOCATIONAL EXCELLENCECentres of Vocational Excellence (CoVE) aim to be a driving force for reforms in the Vocational Education Training (VET) sector, ensuring high quality skills and competences that lead to quality employment and career-long opportunities, meeting the needs of an innovative, inclusive and sustainable economy and contributing to addressing challenges in key economic sectors.The main objective is the establishment of transnational collaborative networks that bring together local and regional VET stakeholders (VET institutions, companies, social partners, authorities, higher education institutions, research institutes, etc.) in strong and broad partnerships, thereby creating comprehensive skills ecosystems for innovation, regional development, and social inclusion.The initiative is based on a bottom-up approach to vocational excellence, enabling VET instit...

This program is intended to support Tribal and Urban Indian communities in strengthening dementia care and services for American Indian and Alaska Native (AI/AN) people. Rooted in Indigenous values and community self-determination, the program will fund meaningful, measurable improvements that span the full dementia care continuum, from early recognition to caregiver support. Option A – Dementia CAReS (Care Access, Resources, and Support). One national awardee will coordinate four integrated priorities: Mini-Project Funding to help Tribal and Urban Indian clinics launch culturally tailored services. A Dementia Champion Network connecting frontline leaders. Success Sharing through case studies and toolkits. Evaluation & Data using common performance measures and dashboards. Option B – Dementia Caregiver Support and Training Center. One national awardee will deliver dementia caregiver support training, services, resources, and technical assistance. Services will support Tribes, Tribal Organizations, and Urban Indian Organizations. The awardee will develop and implement a comprehensive, culturally relevant caregiver support and training model. It will prioritize leadership, caregiver support, and knowledge and skills development. Across both options, recipients will document emerging practices using standardized measures. These measures will guide continuous quality improvement and improve outcomes for AI/AN people and their caregivers.

The U.S. Department of State’s Embassy N’Djamena announces an open competition to implement a program to build lasting partnerships that promote American excellence and closer U.S.-Chad Ties. Programs funded under this competition will build strong relationships between the U.S. and Chad, with targeted participants including, but not limited to, students, USG exchange program alumni, business leaders, or journalists, while showcasing the United States as a preferred partner in education, technology, commerce, or other areas where the United States has internationally recognized innovation and expertise.

This Funding Opportunity Announcement (FOA) encourages grant applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. BTRCs also make their technologies available to other investigators, train members of the research community in the use of the technologies, and disseminate the technologies broadly.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects.

This initiative seeks to solicit applications for research projects that address the link between social disconnection including both objective social isolation as well as perceived social isolation (otherwise known as loneliness) and suicide in late-life. Emphasis is placed on research that identifies neurobiological and environmental mechanisms associated with social isolation and loneliness that increase risk for suicidal thoughts and behavior in late-life, that uses an experimental therapeutics approach to identify targets and develop and test interventions to prevent late-life suicide, and that develops new and modifies existing service delivery models to enhance social connection in late-life to prevent suicide.

This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic ta...

Although the majority living with schizophrenia and related disorders are over 35 years old, including those first diagnosed and those aging with the illness, the mechanisms underlying the generation and trajectory of the illness remain poorly understood. The purpose of this initiative is to advance translational research to better understand the emergence and trajectory of schizophrenia and related disorders in mid to late life, and to identity targets for future development of prevention and treatment efforts.

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advanceadavnce mechanistic understanding of both biobehavioral and neurobiologfical pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD.